Thursday, December 29, 2011
International Stem Cell Corporation - "How Is Parthenogenesis Done?"
San Diego Research Ethics ConsortiumSalk Institute for Biological Studies
Parthenogenetic stem cell lines: Ethical considerations
International Stem Cell’s Director of Research and Therapeutic Development, Nikolay Turovets, PhD, presents “How is Parthenogenesis Done?”
How is Parthenogenesis Done? (ANIMATED) Posted by PSEO at 8:40 AM
Labels: homozygous, human parthenogenetic stem cells, International Stem Cell Corporation, nikolay turovets, parthenogenesis, pluripotent, stem cell research
Friday, December 16, 2011
RegBlog: Over-Regulation of Parthenotes Stifles Valuable Scientific Research - by Sean J. Kealy
A recent article in Scientific American questioned whether research on stem cell lines derived from unfertilized eggs was too tightly regulated by the federal government. Now that technology allows the creation of stem cells without fertilization, there is no question that federal laws and guidelines are overly restrictive, causing a detrimental effect on valuable scientific inquiry.
Since 1996, Congress has included the Dickey-Wicker Amendment in the annual federal budget. This amendment was a conservative reaction to what some considered to be scientific research that showed little respect toward life.
For example, speaking to the Senate in 1996, Robert Smith (R-NH) said, “Just because a private party wants to destroy life, why should Government force taxpayers to give their blessing to that act? Let private parties use private money for their ethically challenged experiments.” Similarly, Representative Jay Dickey (R-AR) said, also in 1996, that embroyonic research was “an attack on the sanctity of life,” and pointed out that several pro-life organizations supported the amendment.
Please click here to read the complete article.
Posted by PSEO at 8:38 AM
Labels: biotechnology, dickey-wicker, embryonic stem cells, International Stem Cell Corporation, ISCO, parthenotes, stem cell regulation
Thursday, December 15, 2011
Fox News: Stem Cell Cream Shows Benefits Similar to Collagen Injections
Could a stem cell skin care line be coming to a store near you?
Researchers from the International Stem Cell Corporation said they have discovered a new class of pluripotent stem cells that have the same characteristics as embryonic stem cells – but don’t require destroying human embryos.
Dr. Simon Craw, vice president of the International Stem Cell Corporation, said extracts from these stem cells—called parthenogenetic stem cells—have shown benefits regarding skin care.
The scientists stumbled upon the discovery while doing stem cell research for the treatment of Parkinson’s disease. They essentially cracked open the cells and removed the proteins and peptides from the inside to use as part of a mixture for a topical skin cream.
Posted by PSEO at 12:32 PM
Labels: International Stem Cell Corporation, ISCO, Lifeline skin care, parthenogenetic, pluripotent, stem cell skin cream
Wednesday, December 14, 2011
Human Parthenogenetic Stem Cell Derived Neuronal Cells as a Tool for Parkinson’s Disease Treatment by Dr. Ruslan Semechkin
Posted by PSEO at 9:05 AM
Labels: differentiation, homozygous, human embryonic stem cells, International Stem Cell Corporation, parkinsons disease, pluripotent, ruslan semechkin, stem cell research
Thursday, December 1, 2011
International Stem Cell Corporation to Present at the 4th Annual LD MICRO Growth Conference on December 8th
International Stem Cell Corporation (OTCBB:ISCO) today announced that Co-Chairman Ken Aldrich and President and Chief Operating Officer Kurt May will be presenting at the 4th Annual LD MICRO Growth Conference in Los Angeles on Thursday, December 8, 2011 at 2:30 p.m. Pacific. The conference is being held at the Luxe Sunset Boulevard Hotel.
LD Micro founder Chris Lahiji stated, "We are excited to host over 100 companies for the first time in our history. What makes us especially proud, however, are all the interesting companies from our own backyard in Southern California, such as International Stem Cell, that are presenting this year."
About International Stem Cell Corporation
International Stem Cell Corporation is focused on the therapeutic applications of human parthenogenetic stem cells (hpSCs) and the development and commercialization of cell-based research and cosmetic products. ISCO's core technology, parthenogenesis, results in the creation of pluripotent human stem cells from unfertilized oocytes (eggs). hpSCs avoid ethical issues associated with the use or destruction of viable human embryos. ISCO scientists have created the first parthenogenic, homozygous stem cell line that can be a source of therapeutic cells for hundreds of millions of individuals of differing genders, ages and racial background with minimal immune rejection after transplantation. hpSCs offer the potential to create the first true stem cell bank, UniStemCell™. ISCO also produces and markets specialized cells and growth media for therapeutic research worldwide through its subsidiary Lifeline Cell Technology, and cell-based skin care products through its subsidiary Lifeline Skin Care. More information is available at www.internationalstemcell.com.
To subscribe to receive ongoing corporate communications, please click on the following link:http://www.b2i.us/irpass.asp? BzID=1468&to=ea&s=0.
Forward-looking Statements
Statements pertaining to anticipated developments, potential sales growth and other opportunities for the company and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to statements that contain words such as "will," "believes," "plans," "anticipates," "expects," "estimates,") should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products and the management of collaborations, regulatory approvals, need and ability to obtain future capital, application of capital resources among competing uses, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the company's business, particularly those mentioned in the cautionary statements found in the company's Securities and Exchange Commission filings. The company disclaims any intent or obligation to update forward-looking statements.
International Stem Cell Corporation
Kenneth C. Aldrich, Co-Chairman
760-940-6383
kaldrich@intlstemcell.com
or
LHA
Don Markley
310-691-7100
dmarkley@lhai.com
Kenneth C. Aldrich, Co-Chairman
760-940-6383
kaldrich@intlstemcell.com
or
LHA
Don Markley
310-691-7100
dmarkley@lhai.com
Subscribe to:
Posts (Atom)